1
|
Caillaud M, Msheik Z, Ndong-Ntoutoume GMA, Vignaud L, Richard L, Favreau F, Faye PA, Sturtz F, Granet R, Vallat JM, Sol V, Desmoulière A, Billet F. Curcumin-cyclodextrin/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress. Free Radic Biol Med 2020; 161:246-262. [PMID: 32980538 DOI: 10.1016/j.freeradbiomed.2020.09.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 09/09/2020] [Accepted: 09/20/2020] [Indexed: 12/16/2022]
Abstract
The most prevalent form of Charcot-Marie-Tooth disease (CMT type 1A) is characterized by duplication of the PMP22 gene, peripheral dysmyelination and decreased nerve conduction velocities leading to muscle weakness. Recently, oxidative stress was reported as a feature in CMT1A patients. Curcumin exhibits antioxidant activities and has shown beneficial properties on peripheral nerves. However, curcumin presents unfavorable pharmacokinetics. We developed curcumin-cyclodextrin/cellulose nanocrystals (Nano-Cur) to bypass this limitation. The present study investigated the therapeutic potential of Nano-Cur in vitro in Schwann cells (SCs) and in vivo in the transgenic CMT1A rat model. In vitro, Nano-Cur treatment (0.01 μM for 8 h) reduced reactive oxygen species and improved mitochondrial membrane potential in CMT1A SCs. Moreover, Nano-Cur treatment (0.01 μM for 1 week) increased the expression of myelin basic protein in SC/neuron co-cultures. Preliminary in vivo experiments carried out in WT rats showed that intraperitoneal (i.p.) injection of Nano-Cur treatment containing 0.2 mg/kg of curcumin strongly enhanced the bioavailability of curcumin. Afterwards, in 1-month-old male CMT1A rats, Nano-Cur treatment (0.2 mg/kg/day, i.p. for 8 weeks) significantly improved sensori-motor functions (grip strength, balance performance, and mechanical and thermal sensitivities). Importantly, sensory and motor nerve conduction velocities were improved. Further histological and biochemical analyses indicated that myelin sheath thickness and myelin protein expression (myelin protein zero and PMP22) were increased. In addition, oxidative stress markers were decreased in the sciatic nerve and gastrocnemius muscle. Finally, Nrf2 expression and some major antioxidant enzymes were increased in sciatic nerve. Therefore, Nano-Cur significantly improved cellular, electrophysiological, and functional features of CMT1A rats.
Collapse
Affiliation(s)
- Martial Caillaud
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France; Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA
| | - Zeina Msheik
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France
| | - Gautier M-A Ndong-Ntoutoume
- EA7500, PEIRENE Laboratory, Faculty of Science and Technology, University of Limoges, F-87000, Limoges, France
| | - Laetitia Vignaud
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France
| | - Laurence Richard
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France; Reference Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital of Limoges, F-87000, Limoges, France
| | - Frédéric Favreau
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France; Department of Biochemistry, University Hospital of Limoges, F-87000, Limoges, France
| | - Pierre-Antoine Faye
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France; Department of Biochemistry, University Hospital of Limoges, F-87000, Limoges, France
| | - Franck Sturtz
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France; Department of Biochemistry, University Hospital of Limoges, F-87000, Limoges, France
| | - Robert Granet
- EA7500, PEIRENE Laboratory, Faculty of Science and Technology, University of Limoges, F-87000, Limoges, France
| | - Jean-Michel Vallat
- Reference Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital of Limoges, F-87000, Limoges, France
| | - Vincent Sol
- EA7500, PEIRENE Laboratory, Faculty of Science and Technology, University of Limoges, F-87000, Limoges, France
| | - Alexis Desmoulière
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France
| | - Fabrice Billet
- EA6309, Myelin Maintenance and Peripheral Neuropathies, University of Limoges, Faculties of Medicine and Pharmacy, F-87000, Limoges, France.
| |
Collapse
|